Yann A. GAUDUEL
  • E-mail :[email]
  • Phone : +33 1 69 31 97 26
  • Location : Palaiseau, France
Last update 2015-06-25 14:34:48.496

Yann A. GAUDUEL Director of research - Dr ès sciences - PhD Biophysics

Course and current status

  • Scientific and medical educations

1987

HDR equivalence, University Paris XI, Orsay, France

1983  

Doctorat ès Sciences, life sciences, University Paris XI, Orsay, France

1977-1983

Medical education (PCEM-DCEM2), University of Paris XI, UER Kremlin-Bicêtre, France

1978

Ph.D. of Biophysics - University Paris XI, Orsay, France

1971-1977

Scientific education (DEUG, Master, DEA) at University of Maine, University of Rennes, University Paris XI, France

  • Academic and professional positions

Since 2013

Member of International Scientific Council at National Institute of Cancer  (INCa, France)

2010-2014

Member of the European Management Committee COST, Action NanoIBCT (Nanosacle Insights into Ion Beam Cancer Therapy)

Since 2006

Co-founder and director of MELUSYN network  (Medicine and Synchrotron light) - Director of Research 1st Class at INSERM - Head of Low and High Energy Radiation Femtochemistry – Physics-Cancer Interface, LOA, CNRS UMR 7639, Ecole Polytechnique – ENSTA, Palaiseau, France

1990-2005

Director of Research 2ndClass at INSERM - Founder and Head of Bioradical Femtochemistry Group – LOA – UMR 1406 Ecole Polytechnique – ENSTA, Palaiseau, France

1992-2002

Co- Founder and Co-coordinator of CNRS Research Network 1017, CNRS Paris, France

1983-2001

Associate Professor at ENSEA, Cergy Pontoise, France 

1984-1990

Researcher INSERM, U275, LOA, Ecole Polytechnique – ENSTA, Palaiseau, France 

1981-1983

Assistant of biophysics, Medical Faculty Lariboisière-St Louis, University Paris VII, France

1980-1981

Military scientific position, Centre de Défense Nucléaire Biologique et Chimique (CNBC), Vert-le-Petit, France

1978-1980

Assistant of biophysics, Faculty of medicine Lariboisière-St Louis, University Paris VII, France

1976-1978 

DGRST Research granting, University Paris XI, Orsay, France 

Short term scientific missions in ESRF (European Synchrotron Radiation Facility, Grenoble, France) Radiation laboratory (Notre Dame University, USA), Bhabha Atomic Research Centre (Mumbai, India), Argonne National Laboratory (USA)

  • Teaching Activities

Since 2010

Lecture to Master Radiotherapy : Biological effects of ionizing radiations: relationship between Time, Space and Energy deposition, Gustave Roussy Institute, Villejuif, France

Lecture to International Master SERP Chem, University Paris XI, Orsay, France

1983-2001

Associate Professor at Ecole Nationale Supérieure de l’Electronique et de ses Applications (ENSEA), Cergy Pontoise, France. Fundamental aspects of Laser-matter interaction - Radiation biology and biophysics - Radiodiagnostics

  • ·  Domains of expertise

Fundamental sciences

Ultrafast laser science

 

Ultrafast laser spectroscopies (UV-Infrared)

 

Low and High Energy Radiation Femtochemistry (eV - MeV range)

 

Prethermal processes (classical and quantum phenomena)

 

Computed MD simulations

Biomedical sciences

Spatio-temporal radiation biophysics at molecular and cellular levels

 

Medical physics and advanced radiation sources (ultrashort relativistic particle beams, accelerated ions, synchrotron sources)

 

Advanced concepts for pulsed radio-chemotherapies of cancers

Scientific summary

The researches of FemtoChemicalBiology Group at LOA (Ecole Polytechnique - ENSTA, Palaiseau) are developed at the interface of fundamental physical chemistry and biomedical sciences, using ultrashort laser facilities and high-time resolved spectroscopic techniques. They concern the innovating domain of Bioradical Femtochemistry for which photo and radio-induced radical events can be investigated at the time scale of small molecular motions, typically in the temporal range 10-13 – 10-11 s.  At the international level, femtochemistry has been honoured in 1999 by the Nobel Prize in Chemistry, awarded to Prof. Ahmed Zewail (USA).

  • ·  Research developments - Innovating approaches

Since 2003  Implementation of High Energy Radiation Femtochemistry (HERF), using TW-laser plasma accelerator and ultra-short particles bunches in the MeV domain. Investigation of prethermal bioradical processes in condensed phase. Transdisciplinary developpement of advanced spatio-temporal radiation biomedicine: new concepts for real-time nanodosimetry, time dependent molecular EBR for normal and cancerous cells, pulsed cancer radiotherapies at high dose rate (NANOBIODOS project supported by AVIESAN and INCa, 2012-2015).

Spatio-temporal radiation biology represents a newly emerging interdisciplinary research field driven nowadays in strong synergy with the most recent progresses of molecular biology, genomics and proteomics, biomarker detections, X-ray synchrotron micro-imaging, well-defined spatial irradiation with microbeams, pulsed relativistic particle sources delivered by TW laser-plasma accelerators, selective targeting radiopharmaceutical, advanced radiation therapies of cancers.

MELUSYN network organizes regularly thematic days and transdisciplinary joint meetings. In 2009 it has initiated the organization of an international ESF-EMBO conference entitled “Spatio-Temporal Radiation Biology: Transdisciplinary Advances for Biomedical Applications” www.esf.org/conferences/09287.  A Special Issue devoted to this emerging domainhas been published in Mutation Research Reviews (Y.A. Gauduel Ed, 212 pages, 2010) http://sciencedirect.com/science/journal/13835742/704

1984 - 2002 Development of low energy radiation femtochemistry (LERF) in the UV-IR domain and pioneering works on ultrafast dynamics of excited electron and bioradical processes in liquid water, ionic solutions, organized assemblies and biomimetic systems.

1976 – 1984  Biophysical aspects of molecular oxygen activation and oxidative stress during myocardium post-ischemia. Molecular regulation of bioradical pathways.

  • ·  Research valorisation

1984 -1992, collaboration with a cardiac surgery team (Lariboisière hospital, France) for the elaboration of a cardiac transplant preservation process (Cardioplegic Celsior solution). This process has been validated by Food and Drug Administration (USA) in 1999 and is actually distributed by Genzyme all over the world (http://www.genzyme.com).

Image d’exemple